Kymera Shares Rally After AbbVie’s Apogee Deal Spurs Immunology Momentum
Kymera Therapeutics stock climbed sharply in mid-day trading, reaching a new 52-week high after AbbVie agreed to buy Apogee Therapeutics for $135.11 per share, valuing Apogee at roughly $10.9 billion. The transaction, focused on atopic dermatitis and asthma assets, created positive spillover for companies developing similar oral or biologic immunol…